CA3132714A1 - Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy - Google Patents
Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy Download PDFInfo
- Publication number
- CA3132714A1 CA3132714A1 CA3132714A CA3132714A CA3132714A1 CA 3132714 A1 CA3132714 A1 CA 3132714A1 CA 3132714 A CA3132714 A CA 3132714A CA 3132714 A CA3132714 A CA 3132714A CA 3132714 A1 CA3132714 A1 CA 3132714A1
- Authority
- CA
- Canada
- Prior art keywords
- oncolytic virus
- replicon rna
- virus
- synthetic oncolytic
- synthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815611P | 2019-03-08 | 2019-03-08 | |
| US62/815,611 | 2019-03-08 | ||
| PCT/US2020/013069 WO2020185293A1 (en) | 2019-03-08 | 2020-01-10 | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3132714A1 true CA3132714A1 (en) | 2020-09-17 |
Family
ID=69526302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3132714A Pending CA3132714A1 (en) | 2019-03-08 | 2020-01-10 | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11717548B2 (enExample) |
| EP (2) | EP3934673B1 (enExample) |
| JP (2) | JP7561134B2 (enExample) |
| KR (2) | KR20250171410A (enExample) |
| CN (1) | CN113966221B (enExample) |
| AU (1) | AU2020233788A1 (enExample) |
| BR (1) | BR112021017637A8 (enExample) |
| CA (1) | CA3132714A1 (enExample) |
| CO (1) | CO2021013417A2 (enExample) |
| DK (1) | DK3934673T3 (enExample) |
| ES (1) | ES3066636T3 (enExample) |
| FI (1) | FI3934673T3 (enExample) |
| IL (1) | IL285963A (enExample) |
| MX (1) | MX2021010808A (enExample) |
| MY (1) | MY207334A (enExample) |
| PH (1) | PH12021552145A1 (enExample) |
| PT (1) | PT3934673T (enExample) |
| SG (1) | SG11202109514VA (enExample) |
| WO (1) | WO2020185293A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121971599A (zh) | 2019-02-25 | 2026-05-05 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| KR20250171410A (ko) * | 2019-03-08 | 2025-12-08 | 메사추세츠 인스티튜트 오브 테크놀로지 | 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| IL316186A (en) | 2022-04-26 | 2024-12-01 | Strand Therapeutics Inc | Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof |
| CN115227674B (zh) * | 2022-08-05 | 2023-07-04 | 武汉滨会生物科技股份有限公司 | 包封的溶瘤病毒遗传物质及其应用 |
| JP2026502453A (ja) * | 2023-01-12 | 2026-01-23 | バヴァリアン・ノルディック・アクティーゼルスカブ | がんワクチンのための組み換え改変ｓａＲＮＡ（ＶＲＰ） |
| WO2024211865A2 (en) * | 2023-04-07 | 2024-10-10 | Omega Therapeutics, Inc. | Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery |
| CN118147171B (zh) * | 2024-03-08 | 2024-12-06 | 上海复诺健生物科技有限公司 | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 |
| KR20260046366A (ko) | 2023-07-25 | 2026-04-07 | 스트랜드 세러퓨틱스 인코포레이티드 | 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도 |
| WO2025087372A1 (zh) * | 2023-10-27 | 2025-05-01 | 上海元宋生物技术有限公司 | 溶瘤病毒及其用途 |
| CN119479778B (zh) * | 2024-10-16 | 2025-04-25 | 北京悦康科创医药科技股份有限公司 | 一种lnp转染效率预测模型构建方法及装置 |
| CN121081290B (zh) * | 2025-11-12 | 2026-03-10 | 佑嘉(杭州)生物医药科技有限公司 | 一种毛囊靶向递送系统及生发防脱化妆品 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| US11291635B2 (en) * | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| CA2841047A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| WO2014089061A1 (en) * | 2012-12-03 | 2014-06-12 | Yasuko Rikihisa | Ehrlichial invasin for immunization, diagnosis, and cell delivery |
| CN107072946B (zh) * | 2014-09-05 | 2022-01-11 | 诺华股份有限公司 | 用于递送活性剂的脂质和脂质组合物 |
| RU2739794C2 (ru) * | 2014-10-31 | 2020-12-28 | Массачусетс Инститьют Оф Текнолоджи | Доставка биомолекул в клетки иммунной системы |
| WO2016187531A1 (en) * | 2015-05-21 | 2016-11-24 | Ohio State Innovation Foundation | Benzene-1,3,5-tricarboxamide derivatives and uses thereof |
| KR20250171410A (ko) * | 2019-03-08 | 2025-12-08 | 메사추세츠 인스티튜트 오브 테크놀로지 | 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 |
| CN116710079A (zh) * | 2020-07-24 | 2023-09-05 | 斯特兰德生物科技公司 | 包含经修饰的核苷酸的脂质纳米颗粒 |
| US20240140960A1 (en) * | 2021-02-12 | 2024-05-02 | Ohio State Innovation Foundation | Sugar derived lipid nanomaterials and uses thereof |
| CN117897494A (zh) * | 2021-07-09 | 2024-04-16 | 瑞普利科特生物科学公司 | 经修饰的东方马脑炎病毒、自复制rna构建体及其用途 |
| CN117180454A (zh) * | 2022-05-16 | 2023-12-08 | 上海行深生物科技有限公司 | 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法 |
-
2020
- 2020-01-10 KR KR1020257038746A patent/KR20250171410A/ko active Pending
- 2020-01-10 US US16/739,407 patent/US11717548B2/en active Active
- 2020-01-10 MY MYPI2021005045A patent/MY207334A/en unknown
- 2020-01-10 SG SG11202109514VA patent/SG11202109514VA/en unknown
- 2020-01-10 JP JP2021553767A patent/JP7561134B2/ja active Active
- 2020-01-10 MX MX2021010808A patent/MX2021010808A/es unknown
- 2020-01-10 PH PH1/2021/552145A patent/PH12021552145A1/en unknown
- 2020-01-10 EP EP20704372.0A patent/EP3934673B1/en active Active
- 2020-01-10 BR BR112021017637A patent/BR112021017637A8/pt unknown
- 2020-01-10 FI FIEP20704372.0T patent/FI3934673T3/fi active
- 2020-01-10 ES ES20704372T patent/ES3066636T3/es active Active
- 2020-01-10 DK DK20704372.0T patent/DK3934673T3/da active
- 2020-01-10 WO PCT/US2020/013069 patent/WO2020185293A1/en not_active Ceased
- 2020-01-10 EP EP25227099.6A patent/EP4729621A2/en active Pending
- 2020-01-10 CA CA3132714A patent/CA3132714A1/en active Pending
- 2020-01-10 PT PT207043720T patent/PT3934673T/pt unknown
- 2020-01-10 AU AU2020233788A patent/AU2020233788A1/en active Pending
- 2020-01-10 CN CN202080034343.3A patent/CN113966221B/zh active Active
- 2020-01-10 KR KR1020217032460A patent/KR102889984B1/ko active Active
-
2021
- 2021-08-30 IL IL285963A patent/IL285963A/en unknown
- 2021-10-07 CO CONC2021/0013417A patent/CO2021013417A2/es unknown
-
2023
- 2023-06-14 US US18/334,449 patent/US12383589B2/en active Active
-
2024
- 2024-09-20 JP JP2024163492A patent/JP2025011109A/ja active Pending
-
2025
- 2025-07-09 US US19/264,067 patent/US20260061013A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021017637A8 (pt) | 2022-08-16 |
| KR20250171410A (ko) | 2025-12-08 |
| WO2020185293A1 (en) | 2020-09-17 |
| KR102889984B1 (ko) | 2025-11-25 |
| CN113966221B (zh) | 2026-03-31 |
| DK3934673T3 (da) | 2026-04-07 |
| US20200281994A1 (en) | 2020-09-10 |
| PH12021552145A1 (en) | 2022-08-31 |
| ES3066636T3 (en) | 2026-05-13 |
| BR112021017637A2 (enExample) | 2021-11-09 |
| SG11202109514VA (en) | 2021-09-29 |
| CN113966221A (zh) | 2022-01-21 |
| FI3934673T3 (fi) | 2026-03-31 |
| MX2021010808A (es) | 2021-12-15 |
| MY207334A (en) | 2025-02-19 |
| KR20220006041A (ko) | 2022-01-14 |
| US20240024394A1 (en) | 2024-01-25 |
| US20260061013A1 (en) | 2026-03-05 |
| CO2021013417A2 (es) | 2022-01-17 |
| AU2020233788A1 (en) | 2021-10-07 |
| PT3934673T (pt) | 2026-04-07 |
| JP7561134B2 (ja) | 2024-10-03 |
| EP3934673A1 (en) | 2022-01-12 |
| US12383589B2 (en) | 2025-08-12 |
| JP2022524391A (ja) | 2022-05-02 |
| IL285963A (en) | 2021-10-31 |
| EP4729621A2 (en) | 2026-04-22 |
| US11717548B2 (en) | 2023-08-08 |
| EP3934673B1 (en) | 2026-01-07 |
| JP2025011109A (ja) | 2025-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12383589B2 (en) | Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy | |
| ES2279580T3 (es) | Composiciones para administrar genes a celulas de la piel que presentan antigenos. | |
| US20170218369A1 (en) | An antagonistic pd-1 aptamer and its applications in cancer therapy related applications | |
| US20230295257A1 (en) | Lipid nanoparticle comprising modified nucleotides | |
| US20210205475A1 (en) | Mitochondrial optogenetics-based gene therapy for treating cancer | |
| CN119563028A (zh) | 具有分泌抗原和免疫调节物的合成自扩增mRNA分子 | |
| US20240166707A1 (en) | Expression constructs and uses thereof | |
| Zhang et al. | Research progress of mRNA vaccines for infectious diseases | |
| JP6702938B2 (ja) | アンタゴニストｉｃ ｃｔｌａ−４アプタマー及びその免疫活性増強への応用 | |
| US20220403416A1 (en) | Polymer-Encapsulated Viral Vectors for In Vivo Genetic Therapy | |
| US12378289B2 (en) | Recombinant oncolytic viruses for treatment of metastatic cancers | |
| EP4514328A1 (en) | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof | |
| RU2809724C2 (ru) | Синтетический онколитический lnp-репликон рнк и применения для иммунотерапии злокачественных опухолей | |
| KR20260046366A (ko) | 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도 | |
| Brown | Development of Genetic Medicines for the Treatment and Prevention of Infectious Disease, Cancer, and Aging | |
| US20240366740A1 (en) | Interleukin-12 self-replicating rna and methods | |
| Ali | Nanoparticle delivery of molecular agents to tackle HIV latency | |
| TW202604543A (zh) | 於實體腫瘤的ｐ２１工程化單核球及放射療法 | |
| Hasan | Messenger RNA Based Vaccines and Their immunological effect on diseases | |
| IL323863A (en) | Synthetic circuits and uses thereof | |
| De Beuckelaer | mRNA-based vaccines to elicit CD8⁺ T cell immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220923 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250103 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250103 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250103 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250423 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250821 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250905 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251022 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251022 |